Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
ArmaGen Technologies, Inc. Hires Biotech Executive as CEO

LOS ANGELES, Jan. 3, 2013 /PRNewswire/ -- ArmaGen Technologies, Inc., a leader in the delivery of biotherapeutics targeting the central nervous system (CNS), today announced James Callaway, Ph.D. as Chief Executive Office and member of the Board of Directors.  Dr. Callaway was most recently President and CEO of Cebix Inc. and joins ArmaGen with nearly 30 year of experience in biotechnology research and development, including executive leadership positions at Bayer and Elan Pharmaceuticals prior to joining Cebix.

"We are delighted to welcome Dr. Callaway, a respected drug developer and biotech executive, as CEO of ArmaGen. His extensive experience working within the realm of CNS disorders at both small biotech companies and major pharmaceutical firms will be invaluable to ArmaGen as the company develops its product pipeline and platform technology," said William M. Pardridge, MD, Founder and Chief Scientific Officer of ArmaGen. "I am confident that under his leadership, the dedicated staff at ArmaGen will be well positioned to deliver compelling clinical data for our therapeutic candidates."

"I am honored to lead ArmaGen through this period of clinical experimentation and validation. The potential for this proprietary Trojan horse technology to transform the therapeutic options in the area of CNS therapies is very exciting," said Dr. Callaway. "In addition, the specific focus on orphan drug indications within the CNS creates a very attractive development pathway through which to validate this platform technology."

Dr. Callaway will join Dr. Pardridge on the ArmaGen Board of Directors along with Stuart Swiedler, MD, PhD, Martin Heidecker PhD (Boehringer Ingelheim Venture Fund), and Arthur Tzianabos, PhD (Shire plc).

Prior to joining ArmaGen, Dr. Callaway served as President and CEO of Cebix Inc., a biology driven company focused on reducing the sequelae associated with diabetic peripheral neuropathy with a peptide therapeutic.  Previously, Dr. Callaway filled several executive roles during his thirteen-year tenure at Elan Pharmaceutical, including program executive for the Alzheimer's Immunotherapy program (encompassing 5 development candidates including bapinuzumab and AN-1792), head of development and head of pharmaceutical development.  During his tenure at Elan he also led the development and approval of MyoBloc®and the production of Tysabri®.  Prior to Elan, Dr. Callaway had development responsibilities at Bayer Pharmaceuticals in Berkeley, SmithKline Beecham (GSK) in King of Prussia as well as Ingene in Santa Monica (Xoma).  Dr. Callaway received his Ph.D. in Biological Chemistry from UCLA with a focus on peptide chemistry and has filed and defended numerous NDAs and INDs during the course of his career.

Victoria Sergeant & Associates led the successful executive search for this position.

About ArmaGen®Technologies

The ArmaGen molecular Trojan horse technology has the potential to re-engineer recombinant proteins for BBB penetration for the treatment of diseases of the brain and spinal cord. The long-term mission at ArmaGen is the development of BBB-penetrating biopharmaceuticals for diseases of the CNS that affect over 250 million people world-wide. Initially, the company will focus on orphan diseases of the CNS with lead biopharmaceuticals for Mucopolysaccharidosis (MPS) Type I, or Hurler's syndrome and MPS Type II, or Hunter's disease.

ArmaGen Technologies is both a platform technology company and a products company. The platform technology produces IgG fusion proteins formed by fusion of a recombinant protein therapeutic, which does not cross the BBB to an IgG. The IgG domain of the fusion protein is a genetically engineered monoclonal antibody, which crosses the human BBB via transport on endogenous BBB receptors. The IgG domain acts as a molecular Trojan horse to ferry the fused pharmaceutical agent across the BBB from blood.  ArmaGen has used the platform technology to develop a diverse pipeline of BBB penetrating recombinant protein therapeutics, including lysosomal enzymes, neurotrophins, decoy receptors, or therapeutic antibodies.

www.armagen.com

About Victoria Sergeant & Associates

http://vsergeant.com/index.html

Contact:
James Callaway, CEO
858-967-1471
jcallaway@armagen.com

SOURCE ArmaGen Technologies, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
WaveMaker on Tuesday announced WaveMaker Enterprise, licensed software that enables organizations to run their own end-to-end application platform as a service (aPaaS) for building and running custom apps. WaveMaker Enterprise is a commercially available rapid API app development and d...
Whether you're a startup or a 100 year old enterprise, the Internet of Things offers a variety of new capabilities for your business. IoT style solutions can help you get closer your customers, launch new product lines and take over an industry. Some companies are dipping their toes in...
Cloudian on Tuesday announced immediate availability of Cloudian HyperStore appliances and Cloudian HyperStore 5.0 software. Flash-optimized, rack-ready HyperStore appliances make it easy to economically deploy full-featured, highly scalable S3-compliant storage with three enterprise-f...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is ob...
The Domain Name Service (DNS) is one of the most important components in networking infrastructure, enabling users and services to access applications by translating URLs (names) into IP addresses (numbers). Because every icon and URL and all embedded content on a website requires a DN...
The cloud provides an easy onramp to building and deploying Big Data solutions. Transitioning from initial deployment to large-scale, highly performant operations may not be as easy. In his session at 15th Cloud Expo, Harold Hannon, Sr. Software Architect at SoftLayer, will discuss the...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE